Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Jacobus PfistererFlorence Joly LobbedezGunnar B KristensenJoern RauSven MahnerPatricia PautierAhmed El-BalatJean-Emmanuel KurtzUlrich CanzlerJalid SehouliMartin L HeubnerAndreas D HartkopfKlaus BaumannAnnette HasenburgLars C HankerAntje BelauBarbara SchmalfeldtDominik DenschlagTjoung-Won Park-SimonFrédéric SelleChristian JackischAlexander BurgesHans-Joachim LückGünter EmonsWerner MeierMartina Gropp-MeierWillibald SchröderNikolaus de GregorioFelix HilpertPhilipp HarterPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Longer treatment duration with bevacizumab for up to 30 months did not improve PFS or OS in patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer. A bevacizumab treatment duration of 15 months remains the standard of care.